BioPharm urges root-cause quality fixes

BioPharm International’s argument is straightforward: too many pharma quality systems respond to failure by patching the visible problem and moving on. In a January 1, 2020 article, the trade publication said that approach leaves the underlying cause untouched and makes repeat deviations more likely. Agnes Shanley, writing for BioPharm International, said the result is a quality organization stuck in correction instead of prevention. The piece lands on a familiar pressure point for manufacturers, where recurring batch issues, documentation failures and weak investigations can expose gaps in process design, evidence collection or management systems. ### Why does retraining so often show up as the answer? BioPharm International said retraining, revised forms and added checks are common responses when an investigation closes without a deeper finding. Shanley wrote that focusing on symptoms rather than causes “locks teams into a corrective, rather than preventive, mindset,” describing a pattern in which organizations react to the event in front of them instead of redesigning the process that allowed it. (biopharminternational.com) BioPharm International’s broader coverage has made the same point in adjacent terms. A separate article on root-cause determination said human error is rarely a sufficient root cause on its own and that investigations should determine why the failure occurred and how recurrence will be prevented. ### What does a root-cause fix look like in practice? Root-cause work starts with evidence, not a preferred explanation. (biopharminternational.com) BioPharm International’s coverage of deviation investigations says the purpose of a GMP investigation report is to show that the root cause was identified, corrective actions were taken, and product quality was assessed. That framework pushes investigators beyond the immediate event toward process history, equipment, product impact and formal root-cause tools. (biopharminternational.com) A 2020 BioPharm International article on broader quality issues said bio/pharma manufacturers have often relied too heavily on administrative controls to address compliance failures. That article contrasted paperwork-heavy responses with approaches that target system weaknesses and total cost of quality. ### Where does CAPA fit into this? CAPA — corrective and preventive action — is supposed to reduce recurrence, not just document closure. (biopharminternational.com) BioPharm International’s reporting on CAPA has said the process has historically been more corrective than preventive, and that poor data visibility can make it harder to track patterns or determine true root causes. Another BioPharm International article, published in 2024, said effective CAPA requires a focus on “true root causes, not just symptoms.” That piece tied stronger CAPA programs to leadership ownership, comprehensive responses and manufacturing resilience. (biopharminternational.com) ### Why do recurring deviations matter beyond one event? Regulators expect investigations to explain unexplained discrepancies and verify that corrective actions work. (biopharminternational.com) BioPharm International’s article on out-of-specification and root-cause investigations said regulatory agencies require manufacturers to determine root cause and monitor the effectiveness of corrective and preventive actions. (biopharminternational.com) An older BioPharm International article on deviation management said weak investigations can leave system-level gaps undiscovered and increase regulatory risk. The publication described deviation management as a tool for detecting failures early and uncovering weaknesses that can be prevented in the future. ### What is the practical takeaway for quality organizations? The January 1, 2020 article does not call for more paperwork. (biopharminternational.com) BioPharm International said the shift is from closing events quickly to designing responses that remove the conditions that produced them. That can mean reworking process design, strengthening evidence gathering, improving data trending or changing how investigations are scoped. (biopharminternational.com) BioPharm International has continued to publish related material on CAPA effectiveness, root-cause investigations and quality-by-design topics on its site. The original Shanley article remains available there, with later pieces expanding on preventive action, data use and investigation quality. (biopharminternational.com)